Bone Mineral Density Effects of Randomized Regimen and Nucleoside Reverse Transcriptase Inhibitor Selection from ACTG A5142

Overview

Journal HIV Clin Trials

Specialties Infectious Diseases
Pharmacology

Date 2013 Oct 23

PMID 24144899

Citations 15

Authors

Jeannie S Huang

Michael D Hughes

Sharon A Riddler

Richard H Haubrich

Affiliations

Soon will be listed here.

Abstract

Objective: To compare the longitudinal changes in total bone mineral density (TBMD) across antiretroviral (ARV) regimens.

Methods: A5142 was an open-label study comparing 3 ARV regimens for the initial treatment of HIV-1. Subjects were randomized equally to efavirenz (EFV) plus 2 nucleoside reverse transcriptase inhibitors (NRTIs), lopinavir/ritonavir (LPV/r) plus 2 NRTIs, or LPV/r plus EFV without NRTI. The NRTI regimen (lamivudine [3TC] plus zidovudine [ZDV], stavudine [d4T], or tenofovir [TDF]) was selected prior to randomization. TBMD was assessed via whole-body dual-energy X-ray absorptiometry (DXA) at baseline and 48 and 96 weeks. Analysis was modified intent-to-treat (ITT) ignoring regimen changes using all evaluations.

Results: Significant mean declines in TBMD at week 48 were observed among subjects. In repeated-measures analysis of changes (including randomized regimen, NRTI used, and time), there was a significant difference in the NRTI-containing arms in mean percentage change in TBMD at week 48 according to NRTI used (P < .001). Subjects taking ZDV had similar changes to those taking d4T (P = .970), whereas those taking TDF had larger declines (P < .001). There was a nonsignificant trend toward greater mean declines among subjects taking LPV/r versus EFV (P = .080). Overall, TDF-containing regimens demonstrated the greatest losses in TBMD, while EFV regimens without TDF had lesser TBMD reductions even compared to the NRTI-sparing arm. From week 48 to 96, all treatment groups continued to lose TBMD at similar rates.

Conclusions: Among NRTI-containing arms, NRTI selection, especially use of TDF, had a greater effect on TBMD change than randomized regimen. The long-term clinical significance remains to be demonstrated.

Citing Articles

Metabolic Dysfunction-Associated Steatotic Liver Disease in People Living with HIV-Limitations on Antiretroviral Therapy Selection.

Kalopitas G, Arvanitakis K, Tsachouridou O, Malandris K, Koufakis T, Metallidis S Life (Basel). 2024; 14(6).

PMID: 38929725 PMC: 11205092. DOI: 10.3390/life14060742.

Impact of postpartum tenofovir-based antiretroviral therapy on bone mineral density in breastfeeding women with HIV enrolled in a randomized clinical trial.

Stranix-Chibanda L, Tierney C, Sebikari D, Aizire J, Dadabhai S, Zanga A PLoS One. 2021; 16(2):e0246272.

PMID: 33544759 PMC: 7864465. DOI: 10.1371/journal.pone.0246272.

GG attenuates tenofovir disoproxil fumarate-induced bone loss in male mice gut-microbiota-dependent anti-inflammation.

Liu H, Gu R, Li W, Zhou W, Cong Z, Xue J Ther Adv Chronic Dis. 2019; 10:2040622319860653.

PMID: 31321013 PMC: 6610433. DOI: 10.1177/2040622319860653.

Tenofovir Has Minimal Effect on Biomarkers of Bone Health in Youth with HIV Receiving Initial Antiretroviral Therapy.

Kim-Chang J, Wilson L, Chan C, Fischer B, Venturi G, Goodenow M AIDS Res Hum Retroviruses. 2019; 35(8):746-754.

PMID: 31115244 PMC: 6688113. DOI: 10.1089/AID.2018.0270.

A Review of Long-Term Toxicity of Antiretroviral Treatment Regimens and Implications for an Aging Population.

Chawla A, Wang C, Patton C, Murray M, Punekar Y, de Ruiter A Infect Dis Ther. 2018; 7(2):183-195.

PMID: 29761330 PMC: 5986685. DOI: 10.1007/s40121-018-0201-6.

References

Dolan S, Kanter J, Grinspoon S . Longitudinal analysis of bone density in human immunodeficiency virus-infected women. J Clin Endocrinol Metab. 2006; 91(8):2938-45. PMC: 3207203. DOI: 10.1210/jc.2006-0127. View

Bedimo R, Maalouf N, Zhang S, Drechsler H, Tebas P . Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS. 2012; 26(7):825-31. DOI: 10.1097/QAD.0b013e32835192ae. View

Young B, Dao C, Buchacz K, Baker R, Brooks J . Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000-2006. Clin Infect Dis. 2011; 52(8):1061-8. DOI: 10.1093/cid/ciq242. View

Pan G, Wu X, McKenna M, Feng X, Nagy T, McDonald J . AZT enhances osteoclastogenesis and bone loss. AIDS Res Hum Retroviruses. 2004; 20(6):608-20. DOI: 10.1089/0889222041217482. View

Yin M, Shane E . Low bone-mineral density in patients with HIV: pathogenesis and clinical significance. Curr Opin Endocrinol Diabetes. 2010; 13(6):497-502. PMC: 2868191. DOI: 10.1097/MED.0b013e3280109b6c. View

Jacobson D, Spiegelman D, Knox T, Wilson I . Evolution and predictors of change in total bone mineral density over time in HIV-infected men and women in the nutrition for healthy living study. J Acquir Immune Defic Syndr. 2008; 49(3):298-308. PMC: 3930999. DOI: 10.1097/QAI.0b013e3181893e8e. View

Franck H, Munz M . Total body and regional bone mineral densitometry (BMD) and soft tissue measurements: correlations of BMD parameter to lumbar spine and hip. Calcif Tissue Int. 2000; 67(2):111-5. DOI: 10.1007/s00223001124. View

Looker A, Melton 3rd L, Harris T, Borrud L, Shepherd J, McGowan J . Age, gender, and race/ethnic differences in total body and subregional bone density. Osteoporos Int. 2008; 20(7):1141-9. PMC: 3057045. DOI: 10.1007/s00198-008-0809-6. View

Yong M, Elliott J, Woolley I, Hoy J . Low CD4 count is associated with an increased risk of fragility fracture in HIV-infected patients. J Acquir Immune Defic Syndr. 2011; 57(3):205-10. DOI: 10.1097/QAI.0b013e31821ecf4c. View

10.

Haubrich R, Riddler S, DiRienzo A, Komarow L, Powderly W, Klingman K . Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS. 2009; 23(9):1109-18. PMC: 2739977. DOI: 10.1097/QAD.0b013e32832b4377. View

11.

Burgos J, Crespo M, Falco V, Curran A, Imaz A, Domingo P . Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimen. J Antimicrob Chemother. 2012; 67(6):1453-8. DOI: 10.1093/jac/dks057. View

12.

McComsey G, Kitch D, Daar E, Tierney C, Jahed N, Tebas P . Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy.... J Infect Dis. 2011; 203(12):1791-801. PMC: 3100514. DOI: 10.1093/infdis/jir188. View

13.

Zuccotti G, Vigano A, Gabiano C, Giacomet V, Mignone F, Stucchi S . Antiretroviral therapy and bone mineral measurements in HIV-infected youths. Bone. 2010; 46(6):1633-8. DOI: 10.1016/j.bone.2010.02.029. View

14.

Mondy K, Yarasheski K, Powderly W, Whyte M, Claxton S, DeMarco D . Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis. 2003; 36(4):482-90. DOI: 10.1086/367569. View

15.

van Vonderen M, Lips P, van Agtmael M, Hassink E, Brinkman K, Geerlings S . First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir. AIDS. 2009; 23(11):1367-76. DOI: 10.1097/QAD.0b013e32832c4947. View

16.

Dolan S, Huang J, Killilea K, Sullivan M, Aliabadi N, Grinspoon S . Reduced bone density in HIV-infected women. AIDS. 2004; 18(3):475-83. DOI: 10.1097/00002030-200402200-00014. View

17.

McComsey G, Lo Re 3rd V, ORiordan M, Walker U, Lebrecht D, Baron E . Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: a randomized, controlled study. Clin Infect Dis. 2008; 46(8):1290-6. PMC: 2430521. DOI: 10.1086/529384. View

18.

Bruera D, Luna N, David D, Bergoglio L, Zamudio J . Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS. 2003; 17(13):1917-23. DOI: 10.1097/00002030-200309050-00010. View

19.

Nuti R, Martini G . Effects of age and menopause on bone density of entire skeleton in healthy and osteoporotic women. Osteoporos Int. 1993; 3(2):59-65. DOI: 10.1007/BF01623374. View

20.

Cotter E, Ip H, Powderly W, Doran P . Mechanism of HIV protein induced modulation of mesenchymal stem cell osteogenic differentiation. BMC Musculoskelet Disord. 2008; 9:33. PMC: 2330047. DOI: 10.1186/1471-2474-9-33. View